Biotech Investment Analyst — Drug Asset & Company Assessment
Mercor (client confidential) · Remote — US-based or deep US-market experience · Remote
- Pay
- $120–200/hr
- Commitment
- part-time
- Hours / week
- ~15
- Source
- mercor
About this role
Mercor is partnering with a biotech and pharma research team on expert human-evaluation work — creating and critiquing rubrics that analyze commercial drugs and drug-development programs. We're seeking a biotech investment analyst (specialist-fund background) for a paid pilot, with the potential to continue as the work scales. **Responsibilities** - Create and critique rubrics that analyze commercial drugs and drug-development programs - Provide overall company and asset assessment — mechanism, clinical data, competitive position, and value drivers - Judge the quality of an investment-style thesis and flag weak, overconfident, or missing assumptions - Apply your assessment across the pilot's set of companies (~5–10) **Requirements** - US-based biotech / healthcare investment analyst with a specialist-fund background - Familiarity with biotech/pharma development programs - Able to assess a drug asset and the company behind it end-to-end - 5+ years evaluating biotech/pharma companies or assets **Engagement Details** - Duration: Approximately 10–20 hours over a 1–2 week pilot - Remote — US-based **Why Participate** - Help improve expert AI evaluation of drugs and drug-development programs - Recurring engagement for strong contributors
Skills & domains
- ai-training
- rlhf
- sme
- annotation
- Life, Physical, and Social Science